Global pharmaceutical company UCB has acquired the Patient Insights Business of IMIDomics, giving it access to a large, multi-omics dataset for immunology studies. 

IMIDomics’ Patient Insight Business includes over 18 years of clinical and molecular data generation. It integrates epidemiological information, clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples.  

The acquisition will give UCB access to IMIDomics’ skilled personnel and laboratories, proprietary genetics and omics datasets, analytic platform, and established partnerships. 

Alistair Henry, Executive Vice President & Chief Scientific Officer at UCB said: “The acquisition of IMIDomics’ Patient Insight Business represents a significant step in our strategy to build the most robust, human data–driven platform in immune mediated diseases. IMIDomics has spent a decade assembling a dataset and network that are simply not replicable in today’s environment. Integrating these capabilities and welcoming the highly skilled IMIDomics team and the insight they bring will elevate our ability to discover and develop medicines that are truly informed by patient biology.” 

Professor Sara Marsal Founder and Chief Medical Officer of IMIDomics, added: “Our mission has always been to bring the patient, through their biology, clinical journeys, and data, into every stage of drug development. UCB is the ideal partner to scale that mission. With their scientific depth and commitment to innovation, we are confident the Patient Insight Engine will continue to unlock meaningful breakthroughs for people living with IMIDs.”